Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration
By Colin Kellaher
Gilead Sciences is taking a significant stake in smaller biotechnology peer Assembly Biosciences as part of a 12-year partnership aimed at advancing the research and development of novel antiviral therapies.
Gilead and Assembly on Tuesday said the work will initially focus on Assembly's established areas of herpesviruses, hepatitis B virus and hepatitis D virus.
As part of the agreement, Assembly will receive an upfront payment of $100 million, including a $15 million investment by Gilead, which is buying nearly 13.1 million shares at $1.16 apiece, a roughly 60% premium to Monday's closing price of 72.6 cents for the South San Francisco, Calif., company.
The companies said Gilead's initial investment represents 19.9% of Assembly's voting stock, adding that Gilead has agreed to buy up to 29.9% of the South San Francisco, Calif., company's voting stock, subject to certain conditions.
The companies said Gilead, based in Foster City, Calif., can opt-in to obtain exclusive rights for each of Assembly's current and future programs upon payment of an opt-in fee of at least $45 million per program, with Assembly eligible to receive up to $330 million per program in potential regulatory and commercial milestones, along with royalties on sales.
Trading in shares of Assembly was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 17, 2023 07:36 ET (11:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying